Device Trial Radar · NCT05633004
Avicena LVDP Validation Study
Last checked: Nov 19, 2026Latest source record: Dec 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
406
Actual
Start
Sep 27, 2021
Primary completion
Sep 8, 2022
Study completion Sep 30, 2022
Sponsor
- Lead sponsor
- Ventric Health, LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 1, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the relationship between non-invasive measurement of left ventricular diastolic pressure (LVDP) using the Vivio System, compared with invasively measured LVDP via direct measurement during left heart catheterization.
Conditions
- Heart Failure
Interventions
VivioDevice
Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoints are the sensitivity and specificity of the Vivio Cuff System for predicting elevated versus non elevated LVEDP as compared to direct measurement of LVEDP in the combined Cath Lab and Healthy CohortsTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spectrum
Grand Rapids, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.